ArticleThe Journal of antimicrobial chemotherapy2012
In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria.
Article in The Journal of antimicrobial chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comprehensive Review of Nanoparticles in the Fight Against Antimicrobial Resistance.Pathogens (Basel, Switzerland) · 2025Pooled it
- In Vitro Antibacterial Effects ofInternational journal of dentistry · 2026Article
- Emerging green-synthesized nanozymes for microbial applications: toward sustainable antimicrobial technologies.World journal of microbiology & biotechnology · 2025Review
- Titanium dioxide nanoparticles augment Ciprofloxacin activity via Inhibition of biofilm formation for multidrug resistance bacteria in-vitro and insilco prediction study.Scientific reports · 2025Article
- Antimicrobial Nanotubes: From Synthesis and Promising Antimicrobial Upshots to Unanticipated Toxicities, Strategies to Limit Them, and Regulatory Issues.Nanomaterials (Basel, Switzerland) · 2025Review
- In vivo evaluation of selenium-tellurium based nanoparticles as a novel treatment for bovine mastitis.Journal of animal science and biotechnology · 2024Article
- EFFICACY AND SAFETY OF SILVER NANOCOMPOSITES ON RIFAMPICIN-RESISTANT M. TUBERCULOSIS STRAINS.Georgian medical news · 2024Article
- Green synthesis, characterization and applications of Phyllanthus emblica fruit extract mediated chromium oxide nanoparticles.Discover nano · 2024Article
- NHCs silver complexes as potential antimicrobial agents.Inorganica chimica acta · 2024Article
- Antibacterial efficacy of novel bismuth-silver nanoparticles synthesis onFrontiers in microbiology · 2024Article
- Selected strategies to fight pathogenic bacteria.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Development of ZnO/selenium nanoparticles embedded chitosan-based anti-bacterial wound dressing for potential healing ability and nursing care after paediatric fracture surgery.International wound journal · 2023Article
- Antimicrobial Nanomaterials as Advanced Coatings for Self-Sanitizing of Textile Clothing and Personal Protective Equipment.ACS omega · 2023Review
- Hesperidin-, Curcumin-, and Amphotericin B- Based Nano-Formulations as Potential Antibacterials.Antibiotics (Basel, Switzerland) · 2022Article
- An Overview of Antimicrobial Properties of Carbon Nanotubes-Based Nanocomposites.Advanced pharmaceutical bulletin · 2022Review
- Antibacterial approaches in tissue engineering using metal ions and nanoparticles: From mechanisms to applications.Bioactive materials · 2021Review
- Preparation, Characterization and Antimicrobial Properties of Nanosized Silver-Containing Carbon/Silica Composites from Rice Husk Waste.ChemistryOpen · 2021Article
- A Machine Learning Tool to Predict the Antibacterial Capacity of Nanoparticles.Nanomaterials (Basel, Switzerland) · 2021Article
- Nanoparticles as Novel Emerging Therapeutic Antibacterial Agents in the Antibiotics Resistant Era.Biological trace element research · 2021Review
- In Vivo and In Vitro Assessments of the Antibacterial Potential of Chitosan-Silver Nanocomposite Against Methicillin-Resistant Staphylococcus aureus-Induced Infection in Rats.Biological trace element research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesSilver carbenes may represent novel, broad-spectrum antimicrobial agents that have low toxicity while providing varying chemistry for targeted applications. Here, the bactericidal activity of four silver carbene complexes (SCCs) with different formulations, including nanoparticles (NPs) and micelles, was tested against a panel of clinical strains of bacteria and fungi that are the causative agents of many skin and soft tissue, respiratory, wound, blood, and nosocomial infections.
methodsMIC, MBC and multidose experiments were conducted against a broad range of bacteria and fungi. Time-release and cytotoxicity studies of the compounds were also carried out. Free SCCs and SCC NPs were tested against a panel of medically important pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Acinetobacter baumannii (MRAB), Pseudomonas aeruginosa, Burkholderia cepacia and Klebsiella pneumoniae.
resultsAll four SCCs demonstrated strong efficacy in concentration ranges of 0.5-90 mg/L. Clinical bacterial isolates with high inherent resistance to purified compounds were more effectively treated either with an NP formulation of these compounds or by repeated dosing. Overall, the compounds were active against highly resistant bacterial strains, such as MRSA and MRAB, and were active against the biodefence pathogens Bacillus anthracis and Yersinia pestis. All of the medically important bacterial strains tested play a role in many different infectious diseases.
conclusionsThe four SCCs described here, including their development as NP therapies, show great promise for treating a wide variety of bacterial and fungal pathogens that are not easily killed by routine antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.